Lipid Nanoparticles-Mediated mRNA Delivery to the Eye Affected by Ionizable Cationic Lipid
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Siyu Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Eye Research Center, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Eye Hospital, Wenzhou Medical University, Hangzhou, Zhejiang 310018…. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, RNA, Messenger, Eye. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Ionizable lipid serves as the key functional component in lipid nanoparticles (LNPs) for efficient mRNA delivery. This study aims to systematically evaluate clinically approved ionizable lipid DLin-MC3-DMA and SM102-based LNPs for ocular mRNA delivery, with a comprehensive assessment of their physicochemical characteristics, delivery efficiency, and biodistribution patterns within the ocular microenvironment. Enhanced green fluorescence protein or Luc encoding mRNA-loaded LNPs were formulated using microfluidic mixing technology and characterized by dynamic light scattering, ζ-potential measurements, and cryogenic transmission electron microscopy imaging. The two LNP systems with different ionizable cationic lipids demonstrated distinct capabilities for in vitro mRNA transfection and intraocular mRNA delivery following intravitreal administration. Notably, the SM102-LNPs exhibited superior performance compared to the MC3-LNPs, characterized by significantly higher transfection efficiency in retinal cells in vitro, and more efficient ocular expression with minimal systemic distribution in vivo. Safety assessment demonstrated that intravitreal administration of SM102-LNPs maintained excellent long-term biocompatibility throughout a five-month study period. The superior performance of SM102-LNPs establishes a promising platform for ocular mRNA therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Research Center, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Eye Hospital, Wenzhou Medical University, Hangzhou, Zhejiang 310018, China.
- National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
- State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
- Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310018, China.
ORCID-Profile: Zhaoqi Pan, Wencan Wu, Xiangsheng Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Dong, S., Pan, Z., Chang, M., Zhou, J., Zhang, M., Chen, Y., Li, T., Chen, Z., Gao, Y., Xie, S., Wu, W., & Liu, X. (2025). Lipid Nanoparticles-Mediated mRNA Delivery to the Eye Affected by Ionizable Cationic Lipid. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00248
Vancouver
Dong S, Pan Z, Chang M, Zhou J, Zhang M, Chen Y, et al. Lipid Nanoparticles-Mediated mRNA Delivery to the Eye Affected by Ionizable Cationic Lipid. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00248
BibTeX
@article{Dong2025,
author = {Dong, Siyu and Pan, Zhaoqi and Chang, Mengchun and Zhou, Juanjuan and Zhang, Mengke and Chen, Yashuang and Li, Ting and Chen, Ziwen and Gao, Yuwan and Xie, Sitao and Wu, Wencan and Liu, Xiangsheng},
title = {Lipid Nanoparticles-Mediated mRNA Delivery to the Eye Affected by Ionizable Cationic Lipid},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00248}
}
EUVIMED